Dopamine D4 Receptor Antagonists for Cognitive Disorder Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease and cognitive disorders are ineffective in stopping disease progression and lack preventive measures, leading to significant public health burdens due to prolonged disability and increased disease burden over time.
Innovation Solution
Administration of dopamine D4 and serotonin 5-HT2A receptor antagonists, inverse agonists, or partial agonists, potentially in combination with transcranial direct current stimulation, to treat and prevent cognitive disorders, delay their progression, and improve or maintain cognitive function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Alzheimer's disease are used, then symptom management is achieved, but disease progression cannot be stopped and cognitive function deteriorates over time
Solution Approach 1:
The patent applies preliminary action by using dopamine D4 receptor antagonists to prevent cognitive decline before it fully manifests. The treatment is administered to individuals at risk of developing Alzheimer's or those showing early signs, aiming to prevent disease progression rather than merely managing symptoms after full onset. This preventive approach addresses the technical contradiction by stopping disease progression before it severely impacts cognitive function.
Solution Approach 2:
The patent employs parameter changes by modulating dopamine receptor activity, specifically targeting D4 receptors with antagonists that alter neurotransmitter binding and signaling. This pharmacological parameter change affects cognitive function and disease progression mechanisms, providing a way to stop disease progression and maintain cognitive ability longer than current treatments allow.
2Productivity
If transcranial direct current stimulation is used alone, then cognitive function shows initial improvement, but therapeutic benefit cannot be sustained over time
Solution Approach 1:
The patent merges transcranial direct current stimulation (tDCS) with dopamine D4 receptor antagonist administration to create a combined therapy. This combination addresses the technical contradiction by using tDCS for initial cognitive improvement while the pharmacological agent ensures sustained therapeutic benefit over time. The synergistic effect of both treatments provides both immediate and long-term cognitive enhancement.
Solution Approach 2:
The patent ensures continuity of useful action by maintaining both tDCS and pharmacological treatment throughout the therapeutic period. The continuous administration of dopamine D4 antagonists combined with ongoing or periodic tDCS sessions ensures that cognitive function improvement is sustained rather than temporary, directly addressing the duration problem of tDCS alone.
3Loss of time
If preventive measures for cognitive disorder are implemented, then disease onset can be delayed, but treatment options remain limited
Solution Approach 1:
The patent applies universality by developing a treatment approach that can be applied across multiple stages and types of cognitive decline. The dopamine D4 receptor antagonist can be used for prevention in at-risk individuals, treatment of early-stage Alzheimer's, and management of cognitive impairment in other neurological conditions. This multi-functional approach expands treatment options while addressing disease onset delay.
Data Source
AI summary
The present invention relates to the prevention or treatment of cognitive disorders, in which subjects, in particular subjects at risk of developing a cognitive disorder are treated with dopamine D4 (and serotonin 5-HT2A) receptor antagonists, reverse agonists, or partial agonists.